Skip to main content
OpenTrials

Clinical trial condition

Solid Tumor

Explore clinical trials studying Solid Tumor. Study availability and eligibility vary by location and protocol.

717 public trials 251 recruiting studies
Refine in advanced search Browse all conditions

Solid Tumor trial results

Completed

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

NCT03602079

Conditions
Adenocarcinoma, Adnexal Diseases, Bile Duct Cancer, +129 more
Locations
  • Florida Cancer Specialists & Research Institute Sarasota, Florida, United States
  • Beth Israel Deaconess Medical Center Cancer Center Boston, Massachusetts, United States
  • Karmanos Cancer Institute Detroit, Michigan, United States
  • Clinical Research Alliance, Inc. Lake Success, New York, United States
View Trial Details
Completed

M6620 (VX-970) in Selected Solid Tumors

NCT03718091

Conditions
Leiomyosarcoma, Neoplasms, Neoplasms by Histologic Type, +7 more
Locations
  • Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Boston Children Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Completed

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

NCT03989115

Conditions
Adnexal Diseases, Bronchial Diseases, Bronchial Neoplasms, +61 more
Locations
  • Honor Health Research Institute Scottsdale, Arizona, United States
  • City of Hope Duarte, California, United States
  • UC Irvine - Chao Family Comprehensive Cancer Center Orange, California, United States
  • UC Davis Comprehensive Cancer Center Sacramento, California, United States
View all 24 locations
View Trial Details
Completed

Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143

NCT04122625

Conditions
Solid Tumor
Locations
  • University of Florida Gainesville, Florida, United States
  • H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
  • Rush University Medical Center Chicago, Illinois, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
View all 17 locations
View Trial Details
Completed

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

NCT01752920

Conditions
Adenocarcinoma, Biliary Tract Diseases, Biliary Tract Neoplasms, +11 more
Locations
  • Scottsdale Healthcare Research Institute Scottsdale, Arizona, United States
  • Emory University, Winship Cancer Institute Atlanta, Georgia, United States
  • Karmanos Cancer Institute, Detroit Detroit, Michigan, United States
  • Comprehensive Cancer Centers of Nevada Las Vegas, Nevada, United States
View Trial Details
Completed

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

NCT03311412

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations
  • South Texas Accelerated Research Therapeutics (START) Midwest Grand Rapids, Michigan, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
  • NEXT Oncology San Antonio, Texas, United States
  • Princess Margaret Cancer Centre Toronto, Ontario, Canada
View Trial Details
Completed

Oral AMXT 1501 Dicaprate in Combination With DFMO

NCT03536728

Conditions
Advanced Cancer, Cancer, Neoplasms, +2 more
Locations
  • Next Oncology - Austin Midtown Austin, Texas, United States
  • MD Anderson Cancer Center Houston, Texas, United States
  • Next Oncology - San Antonio San Antonio, Texas, United States
  • Virginia Cancer Center Fairfax, Virginia, United States
View Trial Details

Related conditions